GRACELL BIOTECHNOLOGIES INC's ticker is GRCL and the CUSIP is 38406L103. A total of 33 filers reported holding GRACELL BIOTECHNOLOGIES INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,187,051 | +5.6% | 759,393 | +39.7% | 0.02% | -5.6% |
| Q2 2023 | $2,071,446 | +81.6% | 543,687 | -11.3% | 0.02% | +63.6% |
| Q1 2023 | $1,140,512 | +32.3% | 613,179 | +63.6% | 0.01% | +57.1% |
| Q4 2022 | $862,134 | -0.9% | 374,841 | +38.7% | 0.01% | 0.0% |
| Q3 2022 | $870,000 | -38.7% | 270,173 | +4.7% | 0.01% | -50.0% |
| Q2 2022 | $1,419,000 | +192.0% | 257,924 | +589.4% | 0.01% | +180.0% |
| Q2 2021 | $486,000 | -40.9% | 37,413 | -29.8% | 0.01% | -50.0% |
| Q1 2021 | $822,000 | – | 53,313 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 10,881,144 | $31,337,695 | 3.43% |
| Sio Capital Management, LLC | 2,081,216 | $5,993,902 | 1.86% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,375,000 | $3,960,000 | 1.58% |
| TCG Crossover Management, LLC | 3,038,889 | $8,752,000 | 1.29% |
| Logos Global Management LP | 2,525,000 | $7,272,000 | 0.97% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,531,497 | $4,410,711 | 0.80% |
| Orbimed Advisors | 9,308,726 | $26,809,131 | 0.57% |
| GREAT POINT PARTNERS LLC | 579,667 | $1,669,441 | 0.30% |
| Temasek Holdings (Private) Ltd | 9,901,940 | $28,517,587 | 0.17% |
| TANG CAPITAL MANAGEMENT LLC | 159,087 | $458,171 | 0.06% |